Martin Gilbert Pomper
Physician in Baltimore, MD
License number
Maryland C1-0007210
Issued Date
Feb 3, 2004
Expiration Date
Mar 31, 2011
Category
Medical Practice
Type
Physician M.D.
Address
Address
2
Baltimore, MD 21231
Personal information
See more information about Martin Gilbert Pomper at radaris.comName
Address
Phone
101 Churchwardens Rd, Baltimore, MD 21212
101 Churchwardens Rd, Baltimore, MD 21212
1190 Northern Pkwy, Baltimore, MD 21210
1012 Deer Ridge Dr, Baltimore, MD 21210
Professional information
Martin Gilbert Pomper, Owings Mills MD
Specialties:
Nuclear Medicine Specialist
Address:
10373A Reisterstown Rd, Owings Mills, MD 21117
21 Crossroads Dr, Owings Mills, MD 21117
4940 Eastern Ave, Baltimore, MD 21224
21 Crossroads Dr, Owings Mills, MD 21117
4940 Eastern Ave, Baltimore, MD 21224
Education:
University of Illinois, College of Medicine - Doctor of Medicine
University of Illinois (Chicago) - Doctor of Philosophy
Johns Hopkins Hospital - Fellowship - Neuroradiology
Johns Hopkins Hospital - Residency - Nuclear Medicine
Johns Hopkins Hospital - Residency - Radiology
University of Illinois (Chicago) - Doctor of Philosophy
Johns Hopkins Hospital - Fellowship - Neuroradiology
Johns Hopkins Hospital - Residency - Nuclear Medicine
Johns Hopkins Hospital - Residency - Radiology
Board certifications:
American Board of Nuclear Medicine Certification in Nuclear Medicine, American Board of Radiology Certification in Diagnostic Radiology (Radiology)
Dr. Martin G Pomper, Baltimore MD - MD (Doctor of Medicine)
Specialties:
Diagnostic Radiology, Nuclear Medicine
Address:
1550 Orleans St SUITE 492, Baltimore 21287
(410) 955-2789 (Phone), (410) 614-3147 (Fax)
600 N Wolfe St SUITE 1159, Baltimore 21287
(410) 955-2789 (Phone), (410) 614-8238 (Fax)
600 N Wolfe St, Baltimore 21287
JOHNS HOPKINS HOSPITAL
600 N Wolfe St, Baltimore 21287
(410) 955-3071 (Phone), (410) 955-1464 (Fax)
Baltimore Office
4940 Eastern Ave, Baltimore 21224
(410) 550-7900 (Phone), (410) 550-5961 (Fax)
RADIOLOGY SERVICES OF NEW YORK
2777 Hylan Blvd, Staten Island 10306
(718) 979-0100 (Phone), (718) 979-3602 (Fax)
(410) 955-2789 (Phone), (410) 614-3147 (Fax)
600 N Wolfe St SUITE 1159, Baltimore 21287
(410) 955-2789 (Phone), (410) 614-8238 (Fax)
600 N Wolfe St, Baltimore 21287
JOHNS HOPKINS HOSPITAL
600 N Wolfe St, Baltimore 21287
(410) 955-3071 (Phone), (410) 955-1464 (Fax)
Baltimore Office
4940 Eastern Ave, Baltimore 21224
(410) 550-7900 (Phone), (410) 550-5961 (Fax)
RADIOLOGY SERVICES OF NEW YORK
2777 Hylan Blvd, Staten Island 10306
(718) 979-0100 (Phone), (718) 979-3602 (Fax)
Certifications:
Diagnostic Radiology, 1995, Nuclear Medicine, 1995
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Univ Of Il Coll Of Med
Graduated: 1990
The Johns Hopkins Hospital
Univ Of Il Coll Of Med
Graduated: 1990
The Johns Hopkins Hospital
Collagen Mimetic Peptides For Targeting Collagen Strands For In Vitro And In Vivo Imaging And Therapeutic Use
US Patent:
2013016, Jun 27, 2013
Filed:
Nov 16, 2012
Appl. No.:
13/679431
Inventors:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD, US
Yang Li - Baltimore MD, US
Daniel Summerfield - Baltimore MD, US
Allen Yi-Lan Wang - Belle Mead NJ, US
Catherine A. Foss - Baltimore MD, US
Martin G. Pomper - Baltimore MD, US
Yang Li - Baltimore MD, US
Daniel Summerfield - Baltimore MD, US
Allen Yi-Lan Wang - Belle Mead NJ, US
Catherine A. Foss - Baltimore MD, US
Martin G. Pomper - Baltimore MD, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
A61K 49/00, C07K 14/78
US Classification:
424 96, 530356, 530324, 436501
Abstract:
The present invention provides both a caged collagen mimetic peptide (CCMP) having the formula: L-S-Z-[Gly-X-Y]-Gly-X-Y-[Gly-X-Y]; wherein L is one or more detectable moieties; S is one or more spacer molecules; Zis any amino acid where m is an integer of 1 to 10; X is proline or modified proline; Y is proline or modified proline; Gly is glycine; n is an integer from 1 to 20; and Gly is a glycine covalently linked to a cage moiety comprising a labile protecting group, as well as a collagen mimetic peptides lacking the labile protecting group (CMP). The inventions are useful for binding collagen and denatured collagen and/or gelatin both in vitro and in vivo, and are useful for targeting any organ or tissue where collagen is present, and can be used for research and diagnostic imaging (both in vivo and in vitro) and also for in vivo therapeutic applications.
Cancer Imaging With Therapy: Theranostics
US Patent:
2013026, Oct 3, 2013
Filed:
Oct 28, 2011
Appl. No.:
13/881777
Inventors:
Martin Gilbert Pomper - Baltimore MD, US
Hyo-eun Bhang - Cambridge MA, US
Paul Fisher - Richmond VA, US
Hyo-eun Bhang - Cambridge MA, US
Paul Fisher - Richmond VA, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
VIRGINIA COMMONWEALTH UNIVERSITY - Richmond VA
VIRGINIA COMMONWEALTH UNIVERSITY - Richmond VA
International Classification:
A61K 49/00, C12N 15/85, A61K 49/04, A61K 38/20, A61K 51/04
US Classification:
800 10, 424 91, 424 96, 424 173, 424 94, 4353201
Abstract:
Genetic constructs comprising reporter genes operably linked to cancer specific or cancer selective promoters (such as the progression elevated gene-3 (PEG-3) promoter) are provided, as are methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. Transgenic animals in which a reporter gene is linked to a cancer specific or cancer selective promoter, and which may be further genetically engineered, bred or selected to have a predisposition to develop cancer, are also provided.
Psma-Binding Agents And Uses Thereof
US Patent:
2011014, Jun 16, 2011
Filed:
Jul 31, 2009
Appl. No.:
13/057044
Inventors:
Martin Pomper - Baltimore MD, US
Ronnie Charles Mease - Fairfax VA, US
Ying Chen - Timonium MD, US
Ronnie Charles Mease - Fairfax VA, US
Ying Chen - Timonium MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 51/04, C07D 213/81, C07C 273/02, G01N 33/53, A61P 35/00
US Classification:
424 189, 546323, 564 47, 435 721
Abstract:
Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
Imaging Infection With Compounds That Bind To Thymidine Kinase
US Patent:
2013006, Mar 14, 2013
Filed:
Aug 28, 2012
Appl. No.:
13/596632
Inventors:
Martin G. Pomper - Baltimore MD, US
Chetan Bettegowda - Charlotte NC, US
Catherine Foss - Baltimore MD, US
Shibin Zhou - Owings Mills MD, US
Kenneth Kinzler - Baltimore MD, US
Bert Vogelstein - Baltimore MD, US
Chetan Bettegowda - Charlotte NC, US
Catherine Foss - Baltimore MD, US
Shibin Zhou - Owings Mills MD, US
Kenneth Kinzler - Baltimore MD, US
Bert Vogelstein - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 51/04, A61K 49/04, A61K 49/00
US Classification:
424 173, 424 92
Abstract:
The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.
Prostate Specific Membrane Antigen (Psma) Targeted Nanoparticles For Therapy Of Prostate Cancer
US Patent:
2011020, Aug 18, 2011
Filed:
Nov 26, 2008
Appl. No.:
12/744982
Inventors:
Sachin S. Chandran - Highland Park NJ, US
Sangeeta Ray - Ellicott City MD, US
Martin G. Pomper - Baltimore MD, US
Samuel R. Denmeade - Ellicott City MD, US
Ronnie C. Mease - Fairfax VA, US
Sangeeta Ray - Ellicott City MD, US
Martin G. Pomper - Baltimore MD, US
Samuel R. Denmeade - Ellicott City MD, US
Ronnie C. Mease - Fairfax VA, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
A61K 9/14, A61K 48/00, A61K 38/02, A61K 31/70, A61K 38/14, A61P 35/00, A61P 35/04, A61P 35/02, A61P 29/00, A61P 17/06, A61P 17/02, A61P 17/00, A61P 37/08, A61P 25/00, A61P 11/06, A61P 11/00, A61P 9/00, A61P 9/10, A61P 7/02, A61P 9/12, A61P 1/00, A61P 1/04, A61P 31/04, A61P 31/12, A61P 31/18, A61P 31/22, A61P 31/16, A61P 37/06, A61P 19/10, A61P 25/28, A61P 25/16, A61P 25/02, B82Y 5/00
US Classification:
424489, 514 44 R, 514 11, 514 23, 514 209, 977773, 977906
Abstract:
The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
Imaging Agents And Methods Of Imaging Naaladase Or Psma
US Patent:
8227634, Jul 24, 2012
Filed:
May 22, 2008
Appl. No.:
12/154445
Inventors:
Martin Gilbert Pomper - Baltimore MD, US
Jiazhong Zhang - Washington DC, US
Alan P. Kozikowski - Princeton NJ, US
John L. Musachio - Baltimore MD, US
Jiazhong Zhang - Washington DC, US
Alan P. Kozikowski - Princeton NJ, US
John L. Musachio - Baltimore MD, US
International Classification:
C07C 229/00, C07C 241/00, C07C 275/00
US Classification:
560 34, 562560, 564 60
Abstract:
The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express NAALADase and/or PSMA. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express NAALADase and/or PSMA to which the compounds of the invention have an affinity.
Imaging Agents And Methods Of Imaging Naaladase Or Psma
US Patent:
2012027, Nov 1, 2012
Filed:
Jun 29, 2012
Appl. No.:
13/537789
Inventors:
Martin Gilbert Pomper - Baltimore MD, US
Jiazhong Zhang - Washington DC, US
John L. Musachio - Lutherville MD, US
Alan P. Kozikowski - Princeton NJ, US
Jiazhong Zhang - Washington DC, US
John L. Musachio - Lutherville MD, US
Alan P. Kozikowski - Princeton NJ, US
Assignee:
Georgetown University - Washington DC
The Johns Hopkins University - Baltimore MD
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 51/04, C07C 69/78, C07C 323/57
US Classification:
424 189, 562556, 560 83, 424 181
Abstract:
The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express NAALADase and/or PSMA. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express NAALADase and/or PSMA to which the compounds of the invention have an affinity.
Imaging And Therapy Of Virus-Associated Tumors
US Patent:
2011017, Jul 21, 2011
Filed:
Oct 13, 2010
Appl. No.:
12/903842
Inventors:
Martin G. Pomper - Baltimore MD, US
Richard Ambinder - Lutherville MD, US
Jun O. Liu - Clarksville MD, US
Curtis R. Chong - Honolulu HI, US
Jianmeng Chen - Timonium MD, US
Richard Ambinder - Lutherville MD, US
Jun O. Liu - Clarksville MD, US
Curtis R. Chong - Honolulu HI, US
Jianmeng Chen - Timonium MD, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
A61K 51/00, C07F 5/02, C07C 229/66, C07D 261/18, C07D 235/32, C07H 19/09, C07D 209/46, C07F 5/00, C07F 9/00, C12Q 1/70, C12N 5/09, A61P 29/00, A61P 31/12, A61P 35/00, A61P 31/04
US Classification:
424 173, 544229, 562455, 548248, 5483087, 536 285, 548472, 536 2855, 534 15, 534 10, 435 5, 435375
Abstract:
The present invention features compositions and methods for detecting, selecting a treatment method for, monitoring, and treating a neoplasia associated with a viral infection.